ADMA Biologics Inc vs GameStop Corp. — how do they compare? ADMA Biologics Inc trades at $9.95 (market cap $2.22B), while GameStop Corp. trades at $18.5 (market cap $8.44B). The key difference: GameStop Corp. is far larger — about 3.8× ADMA Biologics Inc's market cap, and ADMA Biologics Inc is trading nearer its 52-week high, GameStop Corp. nearer its low. Which is the better fit depends on your goals.
| ADMA | GME | |
|---|---|---|
Market Cap | $2.22B | $8.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $27.69 |
52-Week Low | $7.60 | $18.79 |
Enterprise Value | $2.29B | $4.42B |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
GME trades at $18.79, down 1.93% today, with a bearish technical signal from moving averages but oversold RSI readings. Recent earnings beats and a net income margin of 20.45% highlight improving profitability, though revenue declined to $3.82B in 2025. News indicates potential shifts in the proposed eBay acquisition strategy, moving toward a partnership instead of a full takeover.
The outlook is mixed: strong earnings momentum and low debt-to-asset ratio of 0.28 support upside, but bearish analyst consensus (16.67% buy) and revenue contraction pose risks. Investors face dilution concerns from a $1.4B debt-for-stock swap, while collectibles growth offers opportunity.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.
Read more on GME →